Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Leukemia, acute myeloid (AML), child
Stage/Subtype:  untreated childhood acute myeloid leukemia and other myeloid malignancies
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-23 of 23 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA180886, U10CA098543, NCT01371981
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: 2011-0628, NCI-2012-00038, NCT01471444
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 to 60
Sponsor: NCI
Protocol IDs: NCI-2013-00490, PS1203_A06PAMDREVW01, SWOG-S1203, S1203, U10CA180888, U10CA032102, NCT01802333
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, P30CA015704, FHCRC-2230.00, IR-6771, NCT00789776
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2498.00, NCI-2011-03362, P01CA018029, P30CA015704, NCT01640301
AC220 With 5-Aza or Low Dose Cytarabine
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2012-1047, NCI-2013-02274, P50 CA100632, NCT01892371
Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCT 0813 Haplo, NCT02053545
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 24 months
Sponsor: Other
Protocol IDs: INFT2, NCI-2011-03671, NCT00145626
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 75 and under
Sponsor: NCI, Other
Protocol IDs: 2212.00, NCI-2009-01244, P30CA015704, U19AI096111, P01CA018029, NCT00968630
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 26
Sponsor: Other
Protocol IDs: L 10,321, NYMC 525, NCT01049854
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2010-0284, NCI-2012-01889, NCT01200485
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2206.00, NCI-2010-02222, P30CA015704, P01CA018029, NCT01251575
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: UCBT01, NCI-2011-03700, NCT01328496
Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 75
Sponsor: Other
Protocol IDs: 12-016, NCT01596257
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and under
Sponsor: Other
Protocol IDs: 2011LS158, HM2012-05, NCT01677949
Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device
Phase: Phase II
Type: Treatment
Status: Active
Age: 22 and under
Sponsor: Other
Protocol IDs: CHOP 07/216, NCT01071226
KIR Mismatched Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: HAPNK1, NCI-2013-00609, NCT01807611
Safety Study of Cord Blood Units for Stem Cell Transplants
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, NHLBI
Protocol IDs: 130116, 13-H-0116, NCT01861093
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 months and over
Sponsor: Other
Protocol IDs: 2013-7501, NCT02143830
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Phase: Phase I
Type: Treatment
Status: Active
Age: any age
Sponsor: Other
Protocol IDs: 2009-0855, NCI-2011-02061, NCT01113476
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 9L-11-8, NCI-2013-00447, NCT01801046
Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 1 to 22
Sponsor: Other
Protocol IDs: H-33119, NCT02076997
Start Over